Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
批准号:
9884207
负责人:
TOMASZ SKORSKI
金额:
$38.01万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-08-12 至 2025-02-28
关键词:
ABL1 geneAccelerated PhaseAcute Lymphocytic LeukemiaApoptoticAwardBRCA1 geneBRCA2 geneBiologicalBlast PhaseBone MarrowCellsChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaChronic PhaseCollaborationsDNA Double Strand BreakDNA RepairDNA Repair PathwayDNA lesionDNA-Directed DNA PolymeraseDNA-PKcsDNA-dependent protein kinaseDasatinibDataDefectDiseaseDouble Strand Break RepairGeneticGenetic TranscriptionHematopoietic stem cellsImatinibImmunodeficient MouseIn VitroLIG4 geneLeukemic CellMalignant - descriptorMalignant neoplasm of ovaryMediatingModalityMutationNonhomologous DNA End JoiningOncogenicPathway interactionsPatientsPh+ ALLPharmacologyPhiladelphia ChromosomePhosphotransferasesPlayProliferatingProtein Tyrosine KinaseProto-Oncogene Proteins c-ablRAD52 geneRefractoryReportingResearch SupportResistanceRoleSignal TransductionSomatic MutationTestingTherapeuticTherapeutic EffectTyrosine Kinase InhibitorWorkXenograft procedureacute lymphoblastic leukemia cellcancer celldesignhomologous recombinationimprovedimproved outcomein vivoinhibitor/antagonistleukemialeukemic stem cellleukemogenesismalignant breast neoplasmmutantnew therapeutic targetnovelnovel therapeuticsperipheral bloodpersonalized medicineprecision medicinerepairedresponsetumor
中文摘要
致癌BCR-ABL1酪氨酸激酶将造血干细胞(HSC)转化为白血病干细胞
细胞(LSC)诱导慢性期慢性髓性白血病(CML-CP),以及
费城染色体阳性急性淋巴细胞白血病(Ph + ALL)。CML-CP可以
进展到更高级的加速阶段(CML-AP),随后进入非常
侵袭性急变期(CML-BP)。大多数CML/Ph + ALL患者目前接受以下治疗:
酪氨酸激酶抑制剂(TK),例如伊马替尼、达沙替尼和尼洛替尼。但
由于存在TKI难治性,TKI不太可能"治愈" CML/Ph + ALL患者
细胞(例如,静止的LSC),TKi抗性细胞(例如,增殖携带BCR-ABL1的LSC
激酶T315I突变体)和携带另外的体细胞突变的LSC。因此,新的治疗
需要在应答中根除TKi难治性/耐药性CML/Ph + ALL细胞的方式
患者,并治疗对TKis反应不佳的患者。
CML/Ph + ALL细胞积累更多的DNA双链断裂(DSB),最致命的DNA
病变,比正常同行。白血病细胞可以耐受大量的DSB,
修复机制被改变和过度激活。因此,CML/Ph + ALL细胞是“上瘾”的。
这些途径以在来自大量致死DSB的促凋亡挑战中存活。那里
是正常和BCR-ABL1白血病细胞中DSB修复之间的关键差异。
LSC的修复通常采用依赖于RAD52的DSB修复和依赖于PARP1的DSB修复。
替代性非同源末端连接(Alt-NHEJ),而正常对应物使用
BRCA1/2介导的同源重组(HR)和DNA-PKcs依赖性NHEJ(D-NHEJ)。静态
LSC使用PARP1介导的Alt-NHEJ而不是DNA-PKcs依赖的D-NHEJ,这在LSC中占主导地位。
正常静止期HSC。
由以前的奖项支持的研究表明,遗传和药理学
靶向PARP1和/或RAD52对BCR-ABL1阳性细胞产生合成致死作用。
白血病然而,在CML/Ph + ALL中经常检测到体细胞突变,
TKi和/或进展到更恶性的阶段可以调节对PARP1的反应和/或
RAD52抑制。
我们已经发现DNA聚合酶θ(Pol θ,由POLQ编码)在以下方面起着至关重要的作用:
微同源介导的末端连接(MMEJ),Alt-NHEJ的一个分支。我们的初步数据显示
Pol θ在BCR-ABL 1介导白血病发生中是必需的,Pol θ的靶向作用被消除
CML/Ph + ALL细胞。目的#1旨在确定BCR-ABL1介导的信号传导是否/如何改变Pol θ
探讨Pol θ在CML和Ph + ALL中的作用
细胞目标#2将优化Pol θ抑制剂(Pol θ i),使其适合体内使用。目标#3
专注于Pol θ和/或PARP1和RAD 52针对TKi初治患者的遗传和药理学靶向
和模拟外周血和骨的体外条件下经TKi处理的CML/Ph + ALL
骨髓微环境以及在携带原发性白血病的人源化免疫缺陷小鼠中的体内
异种移植
英文摘要
Oncogenic BCR-ABL1 tyrosine kinase transforms hematopoietic stem cells (HSCs) to leukemia stem
cells (LSCs) to induce chronic myeloid leukemia in chronic phase (CML-CP) and
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). CML-CP may
progress to more advanced accelerated phase (CML-AP), and subsequently to a very
aggressive blast phase (CML-BP). Most CML/Ph+ALL patients are currently treated with
tyrosine kinase inhibitors (TKis) such as imatinib, dasatinib and nilotinib. However, it
is unlikely that TKis will “cure” CML/Ph+ALL patients due to the presence of TKi-refractory
cells (e.g., quiescent LSCs), TKi-resistant cells (e.g., proliferating LSCs carrying BCR-ABL1
kinase T315I mutant) and LSCs carrying additional somatic mutations. Therefore, novel treatment
modalities are needed to eradicate TKi-refractory/resistant CML/Ph+ALL cells in the responding
patients and to treat patients who do not respond favorably to TKis.
CML/Ph+ALL cells accumulate more DNA double strand breaks (DSBs), the most lethal DNA
lesions, than normal counterparts. Leukemia cells can tolerate high numbers of DSBs because the
repair mechanisms are altered and hyper-activated. Therefore, CML/Ph+ALL cells are “addicted”
to these pathways to survive pro-apoptotic challenge from high numbers of lethal DSBs. There
are critical differences between DSB repair in normal and BCR-ABL1 leukemia cells.
Proliferating LSCs usually employ RAD52-dependent DSB repairs and PARP1 –dependent
alternative non-homologous end-joining (Alt-NHEJ), whereas normal counterparts use
BRCA1/2-mediated homologous recombination (HR) and DNA-PKcs –dependent NHEJ (D-NHEJ). Quiescent
LSCs use PARP1-mediated Alt-NHEJ instead of DNA-PKcs –dependent D-NHEJ, which is predominant in
normal quiescent HSCs.
Research supported by previous award demonstrated that genetic and pharmacological
targeting of PARP1 and/or RAD52 exerted synthetic lethal effect against BCR-ABL1 –positive
leukemias. However, somatic mutations often detected in CMLs/Ph+ALLs not responding favorably
to TKi and/or progressing to more malignant stages can modulate the response to PARP1 and/or
RAD52 inhibition.
We have discovered that DNA polymerase theta (Polθ, encoded by POLQ) plays a vital role in
microhomology-mediated end-joining (MMEJ), a branch of Alt-NHEJ. Our preliminary data indicate
that Polθ is essential for BCR-ABL1 –mediated leukemogenesis and that targeting of Polθ eliminated
CML/Ph+ALL cells. Aim #1 is designed to determine if/how BCR-ABL1 –mediated signaling modifies Polθ
to regulate its biological activities and to pinpoint the role of Polθ in CML and Ph+ALL stem
cells. Aim #2 will optimize Polθ inhibitor (Polθi) to be suitable for in vivo use. Aim #3 is
focused on genetic and pharmacological targeting of Polθ and/or PARP1 and RAD52 against TKi-naive
and TKi-treated CMLs/Ph+ALLs in in vitro conditions mimicking peripheral blood and bone
marrow microenvironment and also in vivo in humanized immunodeficient mice bearing primary leukemia
xenografts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
-
批准号:10719088
-
项目类别:
-
资助金额:$70.7万
-
财政年份:2023
-
负责人:TOMASZ SKORSKI
-
依托单位:
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
-
批准号:10374000
-
项目类别:
-
资助金额:$39.96万
-
财政年份:2020
-
负责人:TOMASZ SKORSKI
-
依托单位:
MPN-inducing mutations as biomarkers of synthetic lethality
-
批准号:10444919
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2020
-
负责人:TOMASZ SKORSKI
-
依托单位:
MPN-inducing mutations as biomarkers of synthetic lethality
-
批准号:10652426
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2020
-
负责人:TOMASZ SKORSKI
-
依托单位:
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
-
批准号:10608045
-
项目类别:
-
资助金额:$39.96万
-
财政年份:2020
-
负责人:TOMASZ SKORSKI
-
依托单位:
MPN-inducing mutations as biomarkers of synthetic lethality
-
批准号:10174883
-
项目类别:
-
资助金额:$42.77万
-
财政年份:2020
-
负责人:TOMASZ SKORSKI
-
依托单位:
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia
-
批准号:9897628
-
项目类别:
-
资助金额:$48.67万
-
财政年份:2017
-
负责人:TOMASZ SKORSKI
-
依托单位:
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia
-
批准号:9315519
-
项目类别:
-
资助金额:$48.54万
-
财政年份:2017
-
负责人:TOMASZ SKORSKI
-
依托单位:
Targeting DNA repair to eradicate TKI-refractory/resistant CML
-
批准号:8702641
-
项目类别:
-
资助金额:$53.77万
-
财政年份:2014
-
负责人:TOMASZ SKORSKI
-
依托单位:
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
-
批准号:10357886
-
项目类别:
-
资助金额:$38.8万
-
财政年份:2014
-
负责人:TOMASZ SKORSKI
-
依托单位:
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
-
批准号:10592287
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2014
-
负责人:TOMASZ SKORSKI
-
依托单位:
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."
-
批准号:7984880
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2010
-
负责人:TOMASZ SKORSKI
-
依托单位:
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."
-
批准号:8271268
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2010
-
负责人:TOMASZ SKORSKI
-
依托单位:
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."
-
批准号:8100352
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2010
-
负责人:TOMASZ SKORSKI
-
依托单位:
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."
-
批准号:8463470
-
项目类别:
-
资助金额:$28.95万
-
财政年份:2010
-
负责人:TOMASZ SKORSKI
-
依托单位:
Genome instability in leukemia stem cell
-
批准号:7894807
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2009
-
负责人:TOMASZ SKORSKI
-
依托单位:
Genome instability in leukemia stem cell
-
批准号:7729619
-
项目类别:
-
资助金额:$16.5万
-
财政年份:2009
-
负责人:TOMASZ SKORSKI
-
依托单位:
Genomic instability causes imatinib resistance in CML
-
批准号:7915910
-
项目类别:
-
资助金额:$9.83万
-
财政年份:2009
-
负责人:TOMASZ SKORSKI
-
依托单位:
Genomic instability causes imatinib resistance in CML
-
批准号:8206819
-
项目类别:
-
资助金额:$40.07万
-
财政年份:2008
-
负责人:TOMASZ SKORSKI
-
依托单位:
Genomic instability causes imatinib resistance in CML
-
批准号:7554160
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2008
-
负责人:TOMASZ SKORSKI
-
依托单位:
海外基金